Hit enter to search or ESC to close
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
Investors Menu
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
News Releases
Investor Alerts
Year
All Years
2021
2020
2019
2018
2017
2016
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Oct 25, 2019
IDEAYA Biosciences to Present at Upcoming Investor Conferences
Oct 8, 2019
IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial
Aug 12, 2019
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 11, 2019
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Jul 9, 2019
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations
May 28, 2019
IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
May 22, 2019
IDEAYA Announces Pricing of Initial Public Offering
May 8, 2019
IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions
Mar 29, 2019
Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
Feb 13, 2019
IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
»
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact